Erratum

In: Mosterd B, Arits AHMM, Thissen MRT, Kelleners-Smeets NWJ. Histology-based Treatment of Basal Cell Carcinoma. Acta Derm Venereol 2009; 89: 454–458 Table II is incorrect. The changes are highlighted in the Table below.

Table II. Randomized controlled trials investigating treatment of clinically and histologically confirmed nodular, aggressively growing or recurrent basal cell carcinoma (BCC)

Ref.	Intervention	BCC, n	Localization	Clearance rate (%)	FU period (months)	Cosmetic outcome	Conclusion
Nodular basal cell carcinoma
12	Excision	36	Face (scalpel and neck excluded)	98.3a	48	87% gooda	SE higher CR than RTa SE better CO than RTa
	RT	41		92.5a		69% gooda
30	CS	51	Head and neck area	80.4	60	38.5% goodb	SE and CS comparable CR SE better CO than CS
	Excision	45		91.6		79.8% goodb
31	Excision	53	Limbs, trunk, head/neck (high risk areas excluded)	96c	60	54% excellent/good	SE higher CR than MAL-PDT
	MAL-PDT	52		86 c		87% excellent/good
32	Excision		All (BCC on concave areas excluded)	97.7	36	Not investigated	SE higher CR than ALA-PDT
	ALA-PDT			69.7
Aggressively growing basal cell carcinoma
12	Excision	36	Face (scalpel and neck excluded)	98.3a	48	87% gooda	SE higher CR than RTa SE better CO than RTa
	RT	41		92.5a		69% gooda
28	Excision	199	Face	95.9	60	Not investigated	SE and MMS comparable CR
	MMS	198		97.5
Recurrent basal cell carcinoma
28	Excision	100	Face	97.6	60	Not investigated	MMS higher CR than SE
	MMS	102		87.9

aResults for total study group, including other histological subtypes with no separate analysis available for nodular, aggressively growing and recurrent basal cell carcinoma, respectively, baverage of cosmetic evaluation of 6 persons including professionals and laymen, cnon-responders after 3 months excluded from this analysis.

PDT: photodynamic therapy; SE: surgical excision; CR: clearance rate; FU: follow-up; CO: cosmetic outcome; CS: cryosurgery; RT: radiotherapy; ALA: aminolevulinic acid; MAL: methyl aminolevulinate; MMS: Mohs’ micrographic surgery.